Back to today’s briefing

Story perspectives

Novo Nordisk CEO Faces Investor Scrutiny Amid Bidding War

11/5/2025

27 6

Summary

Story summary

Novo Nordisk's new CEO Mike Doustdar faces investor scrutiny as it prepares third-quarter results amid a Pfizer bidding war.
Novo Nordisk's stock has fallen 50% this year, triggering a board shakeup after Novo Nordisk Foundation seized control.
Analysts focus on Doustdar's plan to revive growth in the obesity market amid rising competition.
Hims & Hers Health Inc. is in preliminary talks with Novo Nordisk to sell a new obesity pill.

1 of 1

Story summary

Novo Nordisk's new CEO Mike Doustdar faces investor scrutiny as it prepares third-quarter results amid a Pfizer bidding war.
Novo Nordisk's stock has fallen 50% this year, triggering a board shakeup after Novo Nordisk Foundation seized control.
Analysts focus on Doustdar's plan to revive growth in the obesity market amid rising competition.
Hims & Hers Health Inc. is in preliminary talks with Novo Nordisk to sell a new obesity pill.